Argos presents positive AGS-003 Phase 2 data for newly diagnosed advanced renal cell carcinoma at ASCO Argos Therapeutics today announced the display of positive interim data from a Stage 2 trial that evaluated the clinical activity, safety and immune response of AGS-003 treatment, given in conjunction with sunitinib, in patients with diagnosed advanced renal cell carcinoma recently ?boldenone undecylenate side effects . The info were discussed June 7 in a poster program at the 46th Annual Getting together with of the American Culture of Clinical Oncology , kept in Chicago, IL.D., Ph.D., Co-Director, Immunotherapy Program for the Blumenthal Cancers Center in Charlotte, NEW YORK and lead writer on the poster.
Following dosing, topics completed testing that assessed their subjective claims and the drugs' effects . The principal endpoint was derived from the scores on a drug liking scale. The subjects reported neutral drug liking ratings for placebo and positive drug liking scores for zolpidem and ketamine, which confirmed study validity. The subjective effects of the 20 mg lorcaserin dose were very similar to those of placebo. Drug liking was significantly lower for the 40 mg and 60 mg lorcaserin doses as compared to zolpidem and ketamine, and subjects demonstrated significant disliking of these supratherapeutic doses of lorcaserin in comparison to placebo. The topics' willingness to take lorcaserin once again for recreational purposes was considerably lower for 40 mg and 60 mg doses when compared with placebo.